Last reviewed · How we verify

extraarticular injection with ropivacaine

Hvidovre University Hospital · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local anesthesia for extraarticular procedures and pain management.

At a glance

Generic nameextraarticular injection with ropivacaine
SponsorHvidovre University Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and blocks nerve conduction in the injected area. When administered as an extraarticular injection, it provides localized anesthesia and analgesia at the injection site and surrounding tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: